中文名称:
3,5,7,8-四氢-2-[4-(三氟甲基)苯基]-4H-噻喃并[4,3-D]嘧啶-4-酮
中文同义词:
一种选择性的WNT通路Β-CATENIN介导的转录抑制剂;3,5,7,8-四氢-2-[4-(三氟甲基)苯基]-4H-硫代吡喃并[4,3-D]嘧啶-4-酮;3,5,7,8-四氢-2-[4-(三氟甲基)苯基]-4H-噻喃并[4,3-D]嘧啶-4-酮;转录抑制剂和轴蛋白稳定剂(XAV-939);XAV 939 3,5,7,8-四氢-2-[4-(三氟甲基)苯基]-4H-硫代吡喃并[4,3-D]嘧啶-4-酮
英文同义词:
xav-939;3,5,7,8-Tetrahydro-2-[4-(trifluoromethyl)phenyl]-4H-thiopyrano[4,3-d]pyrimidin-4-one;XAV 939/NVP-XAV939;CS-300;2-[4-(trifluoromethyl)phenyl]-1,5,7,8-tetrahydrothiopyrano[4,3-d]pyrimidin-4-one;XAV 939, >=98%;SteMolecule;1,5,7,8-Tetrahydro-2-[4-(trifluoroMethyl)phenyl]-4H-thiopyrano[4,3-d]pyriMidin-4-one
相关类别:
细胞生物学试剂;干细胞与Wnt信号;小分子抑制剂;小分子抑制剂，天然产物;Heterocycles;Inhibitors;Intermediates Fine Chemicals;Aromatics;Pharmaceuticals;Sulfur Selenium Compounds;API
沸点
429.3±55.0 °C(Predicted)
溶解度
DMSO: soluble5mg/mL, clear
酸度系数(pKa)
0.23±0.20(Predicted)
生物活性
XAV-939 (NVP-XAV939) 通过抑制tankyrase1/2而选择性抑制Wnt/β-catenin介导的转录，无细胞试验中IC50为11 nM/4 nM，调节轴蛋白水平，而对 CRE， NF-κB和TGF-β无作用。
靶点
Target Value
TNKS2
(Cell-free assay) 4 nM
TNKS1
(Cell-free assay) 11 nM
TNKS2
(Cell-free assay)
4 nM
TNKS1
(Cell-free assay)
11 nM
体外研究
XAV939 是小分子选择性抑制剂，抑制Wnt通路转录因子β-catenin调节的转录，作用于TNKS1和TNKS2时IC50分别为11和4nM。XAV939通过稳定axin和断裂混合物的极限浓度组成促进β-catenin降解， 而稳定axin是通过阻断PAR酶：端锚聚合酶1和2 。2种端锚聚合酶亚型因为axin的高度保守区而相互作用，促进了端锚聚合酶通过泛素-蛋白酶体途径的降解。XAV939抑制Wnt/β-catenin通路活性已经用于多种癌症治疗。 XAV939尤其抑制端锚聚合酶PARP活性。XAV939 明显降低DNA-PKcs蛋白水平, 说明了在维持DNA-PKcs蛋白稳定性时端锚聚合酶PARP活性的关键性。用1.0 μM XAV939处理12小时，DNA-PKcs蛋白水平降低到最低水平，与用DMSO处理的对照组相比，相对表达量小于25%。1.0 μM XAV939治疗人类成淋巴细胞，导致端锚聚合酶1水平明显上升。
体内研究
XAV-939 (3 mL, 10 nM) has a suppressive effect on elevated MMP-13 levels in the rat OA model. XAV-939 (1 mg/mL, i.p.) ameliorates the psoriasiform skin disease induced by IMQ. XAV-939 results in a significant decrease in the IMQ-induced epidermal hyperplasia (indicated by acanthosis) and dermal inflammatory infiltrates in mice.
用途
A tankyrase (TNKS) inhibitor that antagonizes Wnt signaling via stimulation of β-catenin degradation and stabilization of axin. XAV 939 inhibits proliferation of the 渭-catenin-dependent colon carcinom a cell line DLD-1.
